TrialSignal
Clinical trial intelligence report
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04589845
Status
ACTIVE_NOT_RECRUITING
Phase
Phase II
Sponsor
Hoffmann-La Roche
Executive brief
Investment-Ready Snapshot
The TAPISTRY study, sponsored by Hoffmann-La Roche, is a global, multicenter, open-label trial evaluating the safety and efficacy of targeted therapies and immunotherapies in patients with unresectable, locally advanced, or metastatic solid tumors. The trial aims to personalize treatment based on genomic profiling, potentially enhancing therapeutic outcomes.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04589845
Indication
Solid Tumors
Modality
small molecule
Target
Solid Tumors with specific oncogenic genomic alterations or TMB-high
Intervention
Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.